Biomarkers of Response to Immunotherapy in Head and Neck Cancer

Boston, MA US
March 27, 2020 to March 28, 2020

Head and neck squamous cell carcinoma (HNSCC) is a worldwide public health problem and, until recently, cancer patients have had limited effective treatment options. For the first time in 50 years, overall survival (OS) is being impacted in HNSCC patients with the application of immunotherapy. However, only a small subset of HNSCC patients derives clinical benefit.  We plan a symposium series that will bring together thought leaders in the field of head and neck cancer in order to foster collaborative and provocative discussions surrounding rapidly evolving concepts in the field of head and neck immuno-oncology.  The theme of our first conference will be assessing the clinical utility of biomarkers in guiding therapy.  Invited speakers will provide perspectives on validated biomarkers of response, on the challenges with implementing biomarker testing in the “real world, ” on optimized workflows to ensure timely biomarker testing, and, lastly, discussions on the next generation of biomarkers of response which are actively being explored in the field. 

Target Audience

This activity is intended for academic and community medical oncologists, head and neck surgeons, radiation oncologists, pathologists, nurse practitioners, nurses, researchers, fellows, residents, and medical students.

Learning Objectives

Upon completion of this activity, learners will be able to:

  1. Discuss at least three pivotal clinical trials that have changed or will be implementing change in the standard of care for head and neck cancer patients.
  2. List 3 biomarkers of response to immunotherapy identified in head and neck cancer patients.
  3. Describe 2 obstacles to achieving timely biomarker testing in the “real world.”

Additional Information

Provided by: 

MGH Departments of Surgery and Otolaryngology - Head & Neck Surgery, Massachusetts Eye & Ear - a Harvard Medical School Affiliate, and Partners HealthCare System


Course summary
Available credit: 
  • 11.25 AMA PRA Category 1 Credit™
  • 11.25 Participation
Course opens: 
Course expires: 
Event starts: 
03/27/2020 - 12:00pm
Event ends: 
03/28/2020 - 5:00pm

The Liberty Hotel
215 Charles Street
Boston, MA 02114
United States


If you are interested in staying at the Liberty Hotel, please use the following link to book your accommodations:

Clint Allen, MD

Investigator and Chief of the Translational Tumor Immunology Section - Head and Neck Surgery Branch
National Institute on Deafness and Other Communication Disorders
National Institutes of Health

Davide Bedognetti, MD, PhD

Principal Investigator – Full Level
Director – Cancer Program
Laboratory of Cancer Immunogenomics - Sidra Medicine
Doha, Qatar

Barbara Burtness, MD

Professor of Medicine, Yale School of Medicine
Director, Head and Neck Cancer Research
Co-Leader, Developmental Therapeutics Program - Yale Cancer Center

William Faquin, MD, PhD

Subspecialty Pathologist, Head and Neck Pathology & Cytopathology - Massachusetts General Hospital
Professor of Pathology, Harvard Medical School

Jerome Galon, PhD

Director of Research, Laboratory of Integrative Cancer Immunology
Chief Inserm Laboratory, INSERM Cordeliers Research Center

Joël Guigay, MD, PhD

Professor, Université Côte d’Azur
Centre Antoine Lacassagne, FHU OncoAge
Nice, France

Howard L. Kaufman, MD

Clinical Associate, Massachusetts General Hospital

Peter P. Lee, MD

Billy Wilder Endowed Professor
Chair, Dept. of Immuno-Oncology
City of Hope Comprehensive Cancer Center

Lisa Licitra, MD, PhD

Director, SC Oncologia medica 3 – “Tumori Testa - Collo”,
Fondazione IRCCS Istituto Nazionale Tumori Milano
Associate Professor of Medical Oncology, Università degli Studi Milano

Jean-Pascal Machiels, MD, PhD

Department of Medical Oncology, Institut Roi Albert II
Cliniques universitaires Saint-Luc
Brussels, Belgium

Sara I. Pai, MD, PhD, FACS

Director, Translational Research in Head and Neck Cancer - Massachusetts General Hospital
Associate Professor of Surgery - Division of Surgical Oncology, Harvard Medical School

Robert Pierce, MD

Member, Program in Immunology
Scientific Director, Immunopathology Lab - Fred Hutchinson Cancer Research Center

Mikael Pittet, PhD

Director, CSB Immunology Program
Professor of Radiology, Harvard Medical School
Massachusetts General Hospital

David L. Rimm MD, PhD

Department of Pathology - Yale University School of Medicine

Peter Sadow, MD, PhD

Director, Head and Neck Pathology - Massachusetts General Hospital 
Associate Professor of Pathology, Harvard Medical School

Jonathan Schoenfeld MD, MPH

Dana-Farber / Brigham and Women’s Cancer Center
Harvard Medical School

Lillian L. Siu, MD, FRCPC

Professor, University of Toronto
Medical Oncologist, Princess Margaret Cancer Centre
Director, Phase I Program
BMO Financial Group Chair, Precision Genomics
Princess Margaret Cancer Centre

Roland K. Strong, PhD

Member, Division of Basic Sciences - Fred Hutchinson Cancer Research Center

Jan B. Vermorken, MD, PhD

Emeritus Professor of Oncology
Department of Medical Oncology, Antwerp University Hospital
Edegem, Belgium

Lori Wirth, MD

Medical Director, Head and Neck Oncology - Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School


Partners HealthCare System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for Physicians.

Partners HealthCare System designates this live activity for a maximum of 11.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 11.25 AMA PRA Category 1 Credit™
  • 11.25 Participation


Please login or register to take this course.

In accordance with the American with Disabilities Act, our Course Coordinator can assist you with any special needs (i.e., physical, dietary, etc). Please contact Ms. Kayla Roche prior to the live event at 617-726-5251.

Registration Fees
Industry: clinical professionals affiliated with pharmaceutical or medical device companies who meet the criteria for target audience$1000
Professionals: individuals affiliated with hospitals, universities, or private practices$250 (default)
Patients, Residents & Medical StudentsFree of Charge


If you are interested in staying at the Liberty Hotel, please use the following link to book your accommodations:


The EthosCE standard install will support the two most recent stable releases of the following browsers for all public pages, both authenticated users and anonymous: Edge, Firefox, Google Chrome, Safari, Firefox. EthosCE supports these browsers by default. Other browsers may work also; however, non-listed browsers are not officially supported.